🌟 An update on our exciting progress in learning and predicting the effects of small molecules on the transcriptome! 🌟
transcriptabio.com/post/mastering…
Today, we announced a new research collaboration with @MayoClinic focused on autism spectrum disorder.
By combining clinical genomics, RNA sequencing and our transcriptomic drug discovery platform, we aim to identify shared disease biology that could inform targeted treatments.
Today, we announced a research collaboration and licensing agreement with @MayoClinic to advance the discovery of new treatments for amyotrophic lateral sclerosis (ALS).
Today we announced results from our research collaboration with @SynfiniInc, which produced a validated-quality lead candidate targeting MSH3, a gene increasingly understood to drive the progression of Huntington’s disease, in just a few weeks.